Free Trial

Amphastar Pharmaceuticals (AMPH) Competitors

Amphastar Pharmaceuticals logo
$26.87 -0.54 (-1.97%)
Closing price 04:00 PM Eastern
Extended Trading
$26.86 -0.01 (-0.02%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMPH vs. CRSP, TGTX, PTCT, MENS, ACLX, PCVX, KRYS, ARWR, ACAD, and ADMA

Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arcellx (ACLX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

Amphastar Pharmaceuticals vs. Its Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Amphastar Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$37.31M148.82-$366.25M-$5.43-11.24
Amphastar Pharmaceuticals$731.97M1.71$159.52M$2.6710.06

CRISPR Therapeutics presently has a consensus target price of $71.50, suggesting a potential upside of 17.12%. Amphastar Pharmaceuticals has a consensus target price of $31.60, suggesting a potential upside of 17.60%. Given Amphastar Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.50
Amphastar Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, CRISPR Therapeutics had 12 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.01 beat CRISPR Therapeutics' score of 0.44 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
2 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amphastar Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amphastar Pharmaceuticals has a net margin of 18.64% compared to CRISPR Therapeutics' net margin of -1,229.43%. Amphastar Pharmaceuticals' return on equity of 20.76% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,229.43% -20.05% -17.09%
Amphastar Pharmaceuticals 18.64%20.76%9.68%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMPH vs. The Competition

MetricAmphastar PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.25B$4.32B$5.74B$10.35B
Dividend YieldN/A1.30%5.53%4.58%
P/E Ratio10.0610.9476.3526.43
Price / Sales1.7115.81466.9091.03
Price / Cash5.577.1637.4661.85
Price / Book1.763.4613.186.39
Net Income$159.52M-$134.23M$3.29B$271.22M
7 Day Performance-0.41%4.80%2.50%2.78%
1 Month Performance-11.90%2.26%4.59%7.35%
1 Year Performance-43.30%40.41%73.81%29.74%

Amphastar Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMPH
Amphastar Pharmaceuticals
4.1852 of 5 stars
$26.87
-2.0%
$31.60
+17.6%
-43.6%$1.25B$731.97M10.062,028Positive News
CRSP
CRISPR Therapeutics
3.1896 of 5 stars
$57.84
+2.8%
$71.60
+23.8%
+30.0%$5.12B$37.31M-10.65460Analyst Forecast
TGTX
TG Therapeutics
4.3521 of 5 stars
$31.75
-1.3%
$46.25
+45.7%
+53.0%$5.10B$454.07M85.81290
PTCT
PTC Therapeutics
3.9012 of 5 stars
$58.98
-3.5%
$69.00
+17.0%
+64.8%$4.85B$806.78M8.461,410Positive News
MENS
Jyong Biotech
N/A$51.82
-15.7%
N/AN/A$4.68BN/A0.0031Gap Down
High Trading Volume
ACLX
Arcellx
2.2775 of 5 stars
$75.20
-1.3%
$114.31
+52.0%
-7.9%$4.23B$107.94M-21.9980
PCVX
Vaxcyte
1.9537 of 5 stars
$31.00
-3.6%
$106.25
+242.7%
-70.4%$4.18BN/A-7.54160
KRYS
Krystal Biotech
4.9415 of 5 stars
$155.71
+8.4%
$209.00
+34.2%
-8.4%$4.16B$359.21M31.65210Positive News
High Trading Volume
ARWR
Arrowhead Pharmaceuticals
4.1377 of 5 stars
$28.67
-3.5%
$43.14
+50.5%
+62.5%$4.11B$3.55M-22.40400
ACAD
ACADIA Pharmaceuticals
4.3504 of 5 stars
$24.67
+4.5%
$29.65
+20.2%
+44.9%$3.98B$957.80M18.55510Trending News
Analyst Forecast
Options Volume
Gap Down
Trading Halted
ADMA
ADMA Biologics
3.2744 of 5 stars
$15.30
-5.0%
$27.67
+80.8%
-20.2%$3.84B$426.45M17.79530

Related Companies and Tools


This page (NASDAQ:AMPH) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners